Aussie Scientists To Test Device To Deliver Tailor-Made Cancer Drugs
This article was originally published in PharmAsia News
Executive Summary
Australian researchers expect to begin clinical trials soon to test a new device for delivering chemotherapy to cancer patients. The device is the EnGenlC Delivery Vehicle developed by a pair of Sydney doctors to enable nano cells to enter cancer cells. The EDV is designed to deliver drugs directly to solid tumors such as those involved in colon, head, liver, lung and rectal cancers. One of the developing physicians said successful trials could lead the way in changing treatment from "one size fits all" to tailor-made medicine. (Click here for more
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.